Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
出版信息
Liver Cancer. 2022 May 10;11(3):185-191. doi: 10.1159/000524977. eCollection 2022 Jun.
Abstract
摘要
相似文献
1
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass.抗PD-1/PD-L1抗体联合抗VEGF抗体的联合免疫疗法可能促进肝细胞癌（包括非炎症亚类）中的细胞毒性T淋巴细胞浸润。
Liver Cancer. 2022 May 10;11(3):185-191. doi: 10.1159/000524977. eCollection 2022 Jun.
2
Recent developments with immunotherapy for hepatocellular carcinoma.肝细胞癌免疫治疗的最新进展。
Expert Opin Biol Ther. 2018 Aug;18(8):905-910. doi: 10.1080/14712598.2018.1499722. Epub 2018 Jul 20.
3
Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles.通过抗 PD-L1 抗体偶联白蛋白纳米颗粒的联合化疗和免疫治疗抗癌方法。
Int J Pharm. 2021 Aug 10;605:120816. doi: 10.1016/j.ijpharm.2021.120816. Epub 2021 Jun 20.
4
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.抗 PD-L1 抗体治疗后胶质瘤组织中 CD163 阳性巨噬细胞的浸润及 PI3Kγ 抑制剂作为抗 PD-L1 抗体联合治疗在替莫唑胺耐药鼠神经胶质瘤起始细胞体内模型中的作用。
Brain Tumor Pathol. 2020 Apr;37(2):41-49. doi: 10.1007/s10014-020-00357-z. Epub 2020 Jan 24.
5
Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.抗血管内皮生长因子/血管内皮生长因子受体 2 单克隆抗体及其与 PD-1/PD-L1 抑制剂的联合应用于临床。
Curr Cancer Drug Targets. 2020;20(1):3-18. doi: 10.2174/1568009619666191114110359.
6
Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma.程序性死亡1、配体1和2相关基因及其与肝细胞癌突变、免疫浸润和临床结局的关联
World J Gastrointest Oncol. 2020 Nov 15;12(11):1255-1271. doi: 10.4251/wjgo.v12.i11.1255.
7
B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.B 细胞对于针对检查点阻断的黑色素瘤免疫反应的产生是必需的。
Front Immunol. 2022 May 26;13:794684. doi: 10.3389/fimmu.2022.794684. eCollection 2022.
8
Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells.黄芩素和黄芩苷通过抑制肝癌细胞 PD-L1 表达促进抗肿瘤免疫。
Int Immunopharmacol. 2019 Oct;75:105824. doi: 10.1016/j.intimp.2019.105824. Epub 2019 Aug 19.
9
Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.超薄层状双氢氧化物介导的光热治疗联合 PD-L1 和 NR2F6 的异步阻断抑制肝癌。
J Nanobiotechnology. 2022 Jul 30;20(1):351. doi: 10.1186/s12951-022-01565-9.
10
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.PD-L1 特异性辅助 T 细胞表现出有效的抗肿瘤反应：针对头颈部鳞状细胞癌中 PD-L1 的癌症免疫治疗新策略。
J Transl Med. 2019 Jun 20;17(1):207. doi: 10.1186/s12967-019-1957-5.
引用本文的文献
1
The efficacy of transarterial chemoembolization combined with helical iodine-125 seed implant, lenvatinib and PD-1 inhibitors in patients with hepatocellular carcinoma complicated by main portal vein tumor thrombus: a retrospective study.经动脉化疗栓塞联合螺旋碘-125粒子植入、仑伐替尼及PD-1抑制剂治疗合并门静脉主干癌栓的肝细胞癌患者的疗效：一项回顾性研究
Front Oncol. 2025 May 8;15:1514375. doi: 10.3389/fonc.2025.1514375. eCollection 2025.
2
WNT/β-catenin Signaling and CD8+ Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma.WNT/β-连环蛋白信号通路与 Tremelimumab 联合 Durvalumab 在晚期肝细胞癌中的 CD8+ 肿瘤浸润淋巴细胞。
In Vivo. 2024 Nov-Dec;38(6):2774-2781. doi: 10.21873/invivo.13757.
3
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.低基线CXCL9可预测阿替利珠单抗联合贝伐单抗治疗不可切除肝癌的早期疾病进展
Liver Cancer. 2022 Oct 31;12(2):156-170. doi: 10.1159/000527759. eCollection 2023 Jun.
4
Advances in Immunotherapy for Hepatocellular Carcinoma.肝细胞癌免疫治疗的进展
Cancers (Basel). 2023 Mar 30;15(7):2070. doi: 10.3390/cancers15072070.
5
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.在不可切除肝细胞癌患者中，不中断阿替利珠单抗联合贝伐珠单抗治疗的治疗调整与良好的总生存期和疾病进展时间相关。
Cancers (Basel). 2023 Mar 2;15(5):1568. doi: 10.3390/cancers15051568.
6
IL-32 and IL-34 in hepatocellular carcinoma.肝细胞癌中的白细胞介素-32和白细胞介素-34
Front Med (Lausanne). 2022 Nov 11;9:1051113. doi: 10.3389/fmed.2022.1051113. eCollection 2022.
7
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗序贯根治性转化（ABC转化）用于不可切除、不适合经动脉化疗栓塞术的中期肝细胞癌患者
Liver Cancer. 2022 Jul 27;11(5):399-406. doi: 10.1159/000526163. eCollection 2022 Sep.
8
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.阿替利珠单抗和贝伐单抗对不符合IMbrave150纳入标准的不可切除肝细胞癌患者的疗效及对肝脏功能储备的影响
Cancers (Basel). 2022 Aug 15;14(16):3938. doi: 10.3390/cancers14163938.
9
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?不可切除肝细胞癌全身治疗方案的选择：病因学有影响吗？
Liver Cancer. 2022 Jun 13;11(4):283-289. doi: 10.1159/000525467. eCollection 2022 Jul.
本文引用的文献
1
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.炎症和非炎症 HCC 分类：一种修正的免疫基因组分类。
Gut. 2023 Jan;72(1):129-140. doi: 10.1136/gutjnl-2021-325918. Epub 2022 Feb 23.
2
Clinical Significance of the Duality of Wnt/β-Catenin Signaling in Human Hepatocellular Carcinoma.Wnt/β-连环蛋白信号通路双重性在人类肝细胞癌中的临床意义
Cancers (Basel). 2022 Jan 17;14(2):444. doi: 10.3390/cancers14020444.
3
Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1 and immune desert‑like mouse tumors.抗血管内皮生长因子抗体触发 PD-L1 和免疫荒漠样小鼠肿瘤中抗 PD-L1 抗体的作用。
Oncol Rep. 2022 Feb;47(2). doi: 10.3892/or.2021.8247. Epub 2021 Dec 27.
4
Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.钆塞酸二钠增强MRI肝胆期肝内结节强化程度较高作为不可切除肝细胞癌抗PD-1/PD-L1单药治疗反应不佳的标志物
Liver Cancer. 2021 Aug 19;10(6):615-628. doi: 10.1159/000518048. eCollection 2021 Nov.
5
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.一种针对不适合经动脉化疗栓塞术（TACE）的中期肝癌患者的新型治疗策略：先行全身治疗，随后进行根治性转化治疗。
Liver Cancer. 2021 Oct 12;10(6):539-544. doi: 10.1159/000519749. eCollection 2021 Nov.
6
Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.免疫微环境可预测接受抗PD-1抗体治疗的肝细胞癌患者的生存情况。
Liver Cancer. 2021 Jul;10(4):380-393. doi: 10.1159/000516899. Epub 2021 Jun 9.
7
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab.在淋巴结中 T 细胞的初始激活和 CXCR3 依赖性迁移是预测阿替利珠单抗应答的关键事件。
Sci Rep. 2021 Jul 6;11(1):13912. doi: 10.1038/s41598-021-93113-y.
8
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients.贝伐单抗可改善三阴性乳腺癌患者中成熟树突状细胞和效应T细胞的肿瘤浸润情况。
NPJ Precis Oncol. 2021 Jun 29;5(1):62. doi: 10.1038/s41698-021-00197-w.
9
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.利用抗血管生成药物提高抗肿瘤免疫：机制见解、当前进展和临床挑战。
Cancer Commun (Lond). 2021 Sep;41(9):830-850. doi: 10.1002/cac2.12183. Epub 2021 Jun 17.
10
Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.抗血管生成药物——克服肿瘤内皮细胞不应答和改善免疫治疗效果。
Nat Rev Clin Oncol. 2021 Aug;18(8):527-540. doi: 10.1038/s41571-021-00496-y. Epub 2021 Apr 8.
Zotero 插件